国内外学术动态
Understanding adverse events of immunotherapy:A mechanistic perspective
发布时间:2021-02-01 浏览次数:536

The treatment of many cancers has been revolutionized by immune checkpoint blockade (ICB) as a standard-of-care
therapeutic. Despite many successes, a large proportion of patients treated with ICB agents experience immune-related adverse events (irAEs) in the form of clinical autoimmunity, ranging from mild to life threatening, that can limit cancer treatment. A mechanistic understanding of these irAEs is required to better treat or prevent irAEs and to predict those patients who are susceptible to irAEs. We propose several mechanisms that may contribute to the generation of irAEs: (1) preexisting susceptibility to autoimmunity, (2) aberrant presentation of “self” by the tumor, and (3) loss of tolerance driven by the tumor or tissue microenvironment.

  

  J. Exp. Med. 2020 Vol. 218 No. 1 e20192179